BofA double upgrades Demant on Zeal upside, market outlook

Costco Wholesale

10/06/2026 11:31

** BofA Global Research double upgrades Demant DEMANT.CO to "buy" from "underperform", citing traction for its newly launched hearing device Oticon Zeal and a bright market outlook
** Says Zeal "adds volume to the bull case" and together with a new platform launch and a more dynamic market offsets risks tied to Costco COST.O
** Notes hearing aid sector could see earnings upgrades if second-quarter growth holds near the about 5% seen in the first quarter, making Demant's FY 2026 outlook "look conservative"
** Adds that an upcoming broader platform launch this summer could help the Danish hearing aid maker regain momentum across its existing portfolio after several challenging years
** Sees the stock "appealing" at roughly 11 times 2027 estimated EBITDA, noting short-squeeze potential
** 13 out of the 21 analysts covering the stock rate it "strong buy"/"buy", seven "hold", one "sell" - LSEG data

 (Reporting by Vera Dvorakova)
 ((vera.dvorakova@thomsonreuters.com))